Effect of concurrent beta-blocker use in patients receiving immune checkpoint inhibitors for advanced solid tumorsGeorge Mellgard, Che‐Kai Tsao, Mahalya Gogerly-Moragoda et al.|Journal of Cancer Research and Clinical Oncology|2022Cited by 23
Clinical factors associated with outcome in solid tumor patients treated with immune-checkpoint inhibitors: a single institution retrospective analysisQian Qin, Che‐Kai Tsao, Tomi Jun et al.|Discover Oncology|2022Cited by 12
Risk Factors for Emergency Room and Hospital Care Among Patients With Solid Tumors on Immune Checkpoint Inhibitor TherapyAnish B. Parikh, Che‐Kai Tsao, Xiaobo Zhong et al.|American Journal of Clinical Oncology|2021Cited by 4
Type, timing, and risk factors associated with immune-related adverse event development in patients with advanced genitourinary cancers treated with immune checkpoint inhibitor.Qian Qin, Che‐Kai Tsao, Vaibhav G. Patel et al.|Journal of Clinical Oncology|2020Cited by 2
Characterizing patterns of disease progression in patients with genitourinary cancers treated with immune checkpoint inhibitors.Vaibhav G. Patel, Che‐Kai Tsao, Qian Qin et al.|Journal of Clinical Oncology|2020Cited by 1